新型コロナウイルス感染症 (COVID-19) が蔓延しておりますが、我々Selleckは従業員とビジネスパートナーの安全を保つための複数の対策を実施し、お客様に製品を継続してお届けします。
COVID-19関連製品はこちら

Vismodegib (GDC-0449)

製品コード：S1082

For research use only.

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

CAS No. 879085-55-9

サイズ	価格(税別)
10mM (1mL in DMSO)	JPY 25900
5mg	JPY 16900
10mg	JPY 30200
50mg	JPY 63400
200mg	JPY 156100

代表番号: 03-5615-9297\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（173）

製品安全説明書

Hedgehog/Smoothened阻害剤の選択性比較

相関Hedgehog/Smoothened製品

Smoothened Agonist (SAG) HCl

Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.
SB225002

SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.
SB-334867

SB-334867 is a selective orexin-1 (OX1) receptor antagonist.
Cyclopamine

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
GANT61

GANT61 (NSC 136476) is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation. GANT61 induces apoptosis and activates protective autophagy in LX-2 cells.
Purmorphamine

Purmorphamine (Shh Signaling Antagonist VI), which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM. Purmorphamine can reduce both basal and induced autophagy.
Sonidegib (NVP-LDE225)

Sonidegib (Erismodegib, NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.

Download Inhibitor Catalog

Hedgehog/Smoothened Signaling Pathway Map

生物活性

製品説明

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

ターゲット

Hedgehog ^[1]
(Cell-free assay)

3 nM

体外試験

GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. GDC-0449 prevents multiple ATP-binding cassette (ABC) transporters. GDC-0449 also blocks ABCG2, Pgp, and MRP1-important ABC transporters associated with MDR. GDC-0449 is a potent inhibitor of ABC transporters, ABCG2/BCRP and ABCB1/Pgp, and is a mild inhibitor of ABCC1/MRP1. In ABCG2-overexpressing HEK293 cells, GDC-0449 increases retention of the fluorescent ABCG2 substrate BODIPY-prazosin and resensitizes these cells to mitoxantrone. In Madin-Darby canine kidney II cells engineered to overexpress Pgp or MRP1, GDC-0449 increases the retention of calcein-AM and resensitizes them to colchicine. GDC-0449 also resensitizes human non-small cell lung carcinoma cells NCI-H460/par and NCI-H460/MX20, which overexpress ABCG2 in response to mitoxantrone, to mitoxantrone, and to topotecan or SN-38. The IC50 values of GDC-0449 for prevention of ABCG2 and Pgp are about 1.4 μM and 3.0 μM, respectively. ^[2] GDC-0449 alters intracellular Ca²⁺ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells. ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

IGROV-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Moq3TWM2OD1yLkC3NlQ5KM7:TR?=	MmW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
HCE-T	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUP6NmhHUUN3ME2xMlMzOjR5IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
D-542MG	NGHNbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUnJR\|UxRTFwOE[3N\|ch\|ryP	NIHteoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
23132-87	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFjNW4lKSzVyPUSuOFAyPDdizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
HDLM-2	NF25bFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXvJR\|UxRThwMES3OlYh\|ryP	NUfRWZdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
ACN	Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWL2U5NoUUN3ME24MlUxOTB7IN88US=>	MnPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
HuO-3N1	MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWjsXG5UUUN3ME25MlYxOTB6IN88US=>	NE\0NJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
BHT-101	NFPMdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXrUTYVjUUN3ME2xNU4{QCEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
KYSE-150	NHLrZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoS4TWM2OD1zMT61PFQyKM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
MC-IXC	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIPnWmRKSzVyPUGyMlIzQTJizszN	NF7BU3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
D-423MG	M1rEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnPGTWM2OD1zMj63OlU4KM7:TR?=	MnzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NY	M13jdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYT5SFFsUUN3ME2xOE45QTB\|IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
HOS	M17US2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFftO5lKSzVyPUG1MlY4OTlizszN	M1zOcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NB7	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4TON2lEPTB;MUWuPFkyKM7:TR?=	M3j1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
DMS-273	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVX5Zm1zUUN3ME2xOk43PzF\|IN88US=>	Ml3wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
MDA-MB-361	M1XuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXP5bGFNUUN3ME2xO{4zPzFzIN88US=>	M3m1fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
DU-145	NF36dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2\LZmlEPTB;MUiuN\|Ih\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
NCI-H82	M2f6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{Ti[mlEPTB;MUmuPFM5PiEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWLLZ2N3UUN3ME2yNE4xOTl4IN88US=>	Mm\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
GCT	MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIrSUYlKSzVyPUKwMlg5OjRizszN	Mly4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
C2BBe1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnrmTWM2OD1{MT6xNFU5KM7:TR?=	Mo\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoLkTWM2OD1{MT64OFQyKM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
COLO-829	NUXCdmw6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIO1VHRKSzVyPUKyMlE5PzFizszN	M4izRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
EW-11	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{XncmlEPTB;MkKuPFAzOiEQvF2=	M2eyXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NCI-H526	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4n5NWlEPTB;MkOuOFcyPyEQvF2=	MkHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
SF295	M3PMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M124d2lEPTB;MkSuNFI2OiEQvF2=	NUDLWIV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
D-566MG	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYjJR\|UxRTJ3LkK5OFMh\|ryP	NV;zWFFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
8505C	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV2yT2Z1UUN3ME2yOU43OzNzIN88US=>	NETvRpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
HT-29	M3\pWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYrieY5vUUN3ME2yOk4xPDNzIN88US=>	NE\qeJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
NBsusSR	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWDJR\|UxRTJ4LkiwNFYh\|ryP	NVvhRYVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
BV-173	NHz3[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGTjcYpKSzVyPUK4MlMyQDJizszN	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
CTB-1	M3vsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYPnVG1oUUN3ME2zNE4yODNzIN88US=>	NFW0VGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
JAR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYHJR\|UxRTN{LkWzO\|Eh\|ryP	MmXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
CAMA-1	NYHYPZlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV;ab2J1UUN3ME2zN{41PjF3IN88US=>	M3fVXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CAL-51	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3TZTmlEPTB;M{SuO\|E4PiEQvF2=	Mn[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
A172	NHzjd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkHnTWM2OD1\|Nz60PVIyKM7:TR?=	NWnkZopCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
QIMR-WIL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVGzRmR7UUN3ME2zPE4xPzB6IN88US=>	NIC5TGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
AsPC-1	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFXxd5pKSzVyPUO4MlQ3PTFizszN	NGPSb\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
MKN7	NWG1eGRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH7pUJNKSzVyPUO5MlAxPzlizszN	MmTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
ONS-76	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFPz[ohKSzVyPUSzMlMxPTdizszN	NHzzfpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
RS4-11	NXr0ZldDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWnTWXJvUUN3ME20OE4xPzV{IN88US=>	NGTSSJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
NOS-1	M1LXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkW5TWM2OD12ND62NFMyKM7:TR?=	M4DlcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
A101D	NELMV\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmfaTWM2OD12ND64NFI{KM7:TR?=	M1LBN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HCC1806	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mnm3TWM2OD12Nj6xNVQ5KM7:TR?=	NEDYcFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
CAL-27	M1q4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUPJR\|UxRTR5LkeyOFYh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
BT-549	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXrDd5U5UUN3ME20PE42OzF3IN88US=>	NVvxcmlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	NHLTSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYTqVZNYUUN3ME20PU4zPDF\|IN88US=>	NHXXXWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
A4-Fuk	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGPCXXNKSzVyPUS5Mlg1QSEQvF2=	M2O3WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
OVCAR-4	NVPxVJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4jHNWlEPTB;NUCuNFYxOSEQvF2=	M2\qVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HD-MY-Z	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4TnZ2lEPTB;NUCuO\|c3PCEQvF2=	Mnf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NCI-H292	NGj6ToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmnWTWM2OD13MD64O\|U5KM7:TR?=	M3;sV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
Sk-ChA-1	M3jTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LFUFAvOjYkgKO1NEDPxE1?	NGKzPIU4OiCq	M{LPUGlEPTB;N{SuOVTDuTJwNUlOwG0>	NF\FSo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0NlQ5Oid-MkW3OFI1QDJ:L3G+
Mz-ChA-1	NYLKO3FlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvPNE4zPeLCk{WwJO69VQ>?	NF\xPWI4OiCq	MmPBTWM2OD13ND65O:KyOy52Nd88US=>	NY\teIFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFI1QDJpPkK1O\|QzPDh{PD;hQi=>
Smo-WT	NVjhU2t{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXrJR\|UxyqCxZjCxOOKhdk1?	NXe4[WpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVEyODRpPkK0NlkyOTB2PD;hQi=>
Smo-D473H	NWfhR4htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1P2eGlEPTEEoH;mJFcvOcLizszN	NUjvRXJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVEyODRpPkK0NlkyOTB2PD;hQi=>
K562	M3vGdGZ2dmO2aX;uJGF{e2G7	MnT1NVAh\|ryP	NHTs[oQ4OiCq	NXXYbYF3emWmdXPld{B1cGViZYjwdoV{e2mxbjDv[kBIdGlzwrC=	NEixZZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxPVgzPCd-MkOzNVk5OjR:L3G+
T315I BCR-ABL BaF3	M1PMSmZ2dmO2aX;uJGF{e2G7	M1y4PVExKM7:TR?=	MWi3NkBp	M2fxd5Jm\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gS4xqOcLi	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzOUiyOEc,OjN\|MUm4NlQ9N2F-
TF-1 BCR-ABL	Mn7FSpVv[3Srb36gRZN{[Xl?	MWKxNEDPxE1?	M1TZXVczKGh?	NGXtNoZz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGdtcTIEoB?=	NGXD[oM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxPVgzPCd-MkOzNVk5OjR:L3G+
Shh-Light 2	NYntS3dkTnWwY4Tpc44h[XO\|YYm=		M{fVVFIh\GG7cx?=	NGDPVXFCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IGPtc{BqdiCvb4Xz[UBUcGhvTHnnbJQhOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNpcC2rbnT1Z4VlKEeuaUGtdoVxd3K2ZYKgZYN1cX[rdImgZYZ1\XJiMjDkZZl{KGK7IHT1ZYwudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJI1mfGixZDygTWM2OCB;IECuNFAyPSEQvF2u	Mn\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=
NIH/3T3	NUn2SHNpTnWwY4Tpc44h[XO\|YYm=			Mn\0TY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViTlnIM\|NVOyClZXzsd{BjgSCJbHmt[JVidC2udXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwJF0hOC5yMEKzJO69VS5?	M4rDcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUiwNFEzLz5{N{G4NFAyOjxxYU6=
NIH/3T3 Light2	MV3GeY5kfGmxbjDhd5NigQ>?			NVv6T5p4UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IFzp[4h1OiClZXzsd{BjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMEKzJO69VS5?	M4\USlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Nki4Nlc5Lz5{OE[4PFI4QDxxYU6=
Light2	NInhOGhHfW6ldHnvckBie3OjeR?=		NGnXdmg1QCCqcoO=	Ml;rTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCOaXfoeFIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFfsbU1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwNlQ3KM7:TT6=	MoPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5M{m3NVQoRjJ7N{O5O\|E1RC:jPh?=
HEPM	NUG1[2hFTnWwY4Tpc44h[XO\|YYm=			M1jhRWlvcGmkaYTpc44hd2ZiU1jIJIlvKGi3bXHuJGhGWE1iY3XscJMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSV7IJF0hOC5yMEK4JO69VS5?	NIDWflg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUexOlI6Pid-MUm3NVYzQTZ:L3G+
Shh Light2	NHrTVJlHfW6ldHnvckBie3OjeR?=			M2my[WlvcGmkaYTpc44hd2ZiU1jIJIlvKG2xdYPlJHNpcCCOaXfoeFIh[2WubIOgZpkhT0yLLYLld5BwdnOrdnWg[olz\W[ueTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByMzFOwG0v	Ml76QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MEmwPFAoRjF7M{C5NFgxRC:jPh?=
HEPM	NGiwOHVHfW6ldHnvckBie3OjeR?=			NWHQWlRZUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hcHWvYX6gTGVRVSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gdoVk\XC2b4KtcYVlcWG2ZXSgS4xqOSCvUl7BJIV5eHKnc4Ppc44h[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygTW5JKD1iMD6wNFMh\|ryPLh?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5NUe0NUc,OjB6N{W3OFE9N2F-
C3H10T1/2	NHjxPFhHfW6ldHnvckBie3OjeR?=		MW[yNEBpenN?	NE\WVVlKdmirYnn0bY9vKG:oIGPtc{BqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgeZNqdmdiaIXtZY4hemWlb33ibY5idnRiU1jIJIF{e2W\|c3XkJIF{KGWoZnXjeEBwdiCVTV:vV2hJKHS{YX7zbYVvfCC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCjZoTldkAzOCCqcoOgZpkhT2yrLXz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFnDOVAhRSByLkCwOUDPxE1w	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMESzOkc,OjR7MEC0N\|Y9N2F-
NIH/3T3	M1rk[GZ2dmO2aX;uJIF{e2G7		M2n2VVI1KGi{cx?=	NGq0bXRKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgNlQhcHK\|IHL5JGdtcS2mdXHsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC1JO69VS5?	NX64SnRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
NIH3T3	NYTnOZNUTnWwY4Tpc44h[XO\|YYm=		NWGySo5{PDhiaILz	Mor3TY5pcWKrdHnvckBw\iC\|bX:tcYVlcWG2ZXSgbIVl\2Wqb3egd4lodmGuaX7nJJBifGi5YYmgbY4hdW:3c3WgUmlJO1R\|IHPlcIx{KGW6cILld5NqdmdiR2LFMWx2[yC{ZYDvdpRmeiCpZX7lJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV2FINWmwZIXj[YQhT1KHLVz1Z{Bz\XCxcoTldkBi[3Srdnn0fUBi\nSncjC0PEBpenNiYomgcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xODZizszNMi=>	NWC5R3ZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDNpPkK5OFk6PDh\|PD;hQi=>
Shh-light2	MnjiSpVv[3Srb36gZZN{[Xl?			MnXXTY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHsbY5oKGmwIHj1cYFvKFOqaD3sbYdpfDJiY3XscJMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xODdizszNMi=>	NUjEXolCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
HEK293	MoHSSpVv[3Srb36gZZN{[Xl?		MnzINkBpenN?	M1;3dWRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvbHHi[Yxt\WRiY4njcI9x[W2rbnWg[pJwdSCqdX3hckBUdW9icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAzKGi{czDifUBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yeTygTWM2OCB;IECuNFA4KM7:TT6=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEW1NUc,OjJ{Nki1OVE9N2F-
NIH3T3	NXuxVWI5TnWwY4Tpc44h[XO\|YYm=			MmHLTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC{ZXPldJRweiC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVizWFMh[2WubIOgeJJidnOoZXP0[YQhf2m2aDDHcIkuemWyb4L0[ZIh\2WwZTDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwO\|E4KM7:TT6=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{M{e2OUc,OjR7MkO3OlU9N2F-
NIH/3T3	M{K3ZmZ2dmO2aX;uJIF{e2G7		NITIR5c1QCCqcoO=	NV:4[IhMUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBUd26rYzDo[YRo\WixZz3pcoR2[2WmIFfsbUBtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBFfWGuLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5MUeg{txONg>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2OUS5OEc,OzB{NEm0PVQ9N2F-
NIH3T3	MkTVSpVv[3Srb36gZZN{[Xl?		NUj4[WZVPDhiaILz	NEfJbFZKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGyrbnegbY4hdW:3c3WgUmlJO1R\|IHPlcIx{KHO2YXLsfUB1emGwc3\lZ5Rm\CC5aYToJGdtcS2udXPp[oVz[XOnIHPvcpN1enWldDDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCmdXHsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC3NkDPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh{N{GzOkc,OjZ6MkexN\|Y9N2F-
NIH3T3	M1zWbWZ2dmO2aX;uJIF{e2G7		MVO0PEBpenN?	M3HyWGlvcGmkaYTpc44hd2ZiU3;ubYMucW6mdXPl[EBp\WSpZXjv[{B{cWewYXzsbY5oKGmwIH3veZNmKE6LSEPUN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh[XO\|YYmsJGlEPTBiPTCwMlAxPzJizszNMi=>	NECwZYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkiyNFU2PCd-Mk[4NlA2PTR:L3G+
NIH3T3	MWTGeY5kfGmxbjDhd5NigQ>?		NXvkSJRzPDhiaILz	MmH0TY5pcWKrdHnvckBw\iCVSFigd4lodmGuaX7nJJBifGi5YYmgbY4hdW:3c3WgUmlJO1R\|IHPlcIx{KG2nYYP1doVlKGGodHXyJFQ5KGi{czDifUBIdGlvbIXjbYZmemG\|ZTDy[ZBwenSncjDhd5NigSxiSVO1NEA:KDBwMEC3NkDPxE1w	NH;kNGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3OlM6Pid-MkSxO\|Y{QTZ:L3G+
NIH/3T3	Mo[wSpVv[3Srb36gZZN{[Xl?		MXq0PEBpenN?	NWPDdY9RUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBIdGlvbIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xODd{IN88UU4>	NX7pWJNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFYzODNpPkK0OFg3OjB\|PD;hQi=>
NIH/3T3	NG\HVINHfW6ldHnvckBie3OjeR?=			NUThdmdNUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGK7IFfsbVEudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wNFczKM7:TT6=	NFjYc4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVcxPCd-MkS0NFU4ODR:L3G+
NIH/3T3	NV;oWndnTnWwY4Tpc44h[XO\|YYm=			MUDJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgZ4Fzenmrbnegd5Ri[my7IITyZY5{\mWldHXkJGdtcS2{ZYDvdpRmeiClb37zeJJ2[3RiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygTWM2OCB;IECuNFA4OiEQvF2u	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ2MkGwNUc,Ojh4NEKxNFE9N2F-
C3H10T1/2	NFq3b\|BHfW6ldHnvckBie3OjeR?=		Mof5OkBpenN?	MoHyTY5pcWKrdHnvckBw\iCVQVetbY5lfWOnZDDkbYZn\XKnboTpZZRqd25ib3[gcY92e2VibXXz[Y5kcHmvYXygdIx2emmyb4TlcpQhSzOKMUDUNU8zKGOnbHzzJJRwKGGua3HsbY5mKHCqb4PwbIF1[XOnIIDvd4l1cX[nIH;ld4Vw[myjc4TzJIFnfGW{IE[gbJJ{NCCLQ{WwJF0hOC5yMUGg{txONg>?	M4mxNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
HCC827	M{LmWWZ2dmO2aX;uJIF{e2G7			M332ZmRqe3CuYXPlcYVvfCCxZjDbN2heNWO7Y3zvdIFucW6nIH\yc40hW02RIG[0NFROKG23dHHueEBqdiCpZX\peIlvcWJicnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\WyuczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDBwMEGyNkDPxE1w	NWj0NIZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3PFcyPTZpPkK4O\|g4OTV4PD;hQi=>
C3H10T1/2	NGLJNmJHfW6ldHnvckBie3OjeR?=			NH;vZW5KdmirYnn0bY9vKG:oIGPITEBqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgZpkhT2yrLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODF\|IN88UU4>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdzNkK5Okc,OTl5MU[yPVY9N2F-
S12	NEG0WZZHfW6ldHnvckBie3OjeR?=			MoXMTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViU{GyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC{ZXPldJRwei2vZXTpZZRm\CCJbHmxJI1TVkFiZYjwdoV{e2mxbjDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCLTligQUAxNjBzMzFOwG0v	NHzGcVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3OVc1OSd-MkC4O\|U4PDF:L3G+
TM3	NHjiNYVHfW6ldHnvckBie3OjeR?=		MVK0PEBpenN?	MVHJcohq[mm2aX;uJI9nKEiqIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIGTNN{Bk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBIdGlzIHflcoUh\XiycnXzd4lwdiCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxKD1iMD6wNVMh\|ryPLh?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl5NkKxOUc,OjZ7N{[yNVU9N2F-
NIH/3T3	M3S2SGZ2dmO2aX;uJIF{e2G7			Mmr3TY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKFOvbzDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iR3zpJI1TVkFiZYjwdoV{e2mxbjDifUBTXC2SQ2KgcYV1cG:mLDDJR\|UxKD1iMD6wNVQ1KM7:TT6=	NV\BVY0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
S12	NVWwOnhjTnWwY4Tpc44h[XO\|YYm=		M1jTVlQ5KGi{cx?=	M{XOZ2lvcGmkaYTpc44hd2ZiaIXtZY4hW0iKIIDheIh4[XliaX6gcY92e2ViU{GyJINmdGy\|IHHzd4V{e2WmIHHzJGdNUS2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEG1JO69VS5?	M3XteFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEO4OVI4Lz5{MUSzPFUzPzxxYU6=
NIH/3T3	NWTXWGxETnWwY4Tpc44h[XO\|YYm=			NXX4fIF1UW6qaXLpeIlwdiCxZjDTUW8hcW5ibX;1d4UhVkmKL{PUN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPBS{1qdmS3Y3XkJIhm\GenaH;nMY1m\GmjdHXkJIx2dWmwZYPj[Y5k\SC\|aXfuZYxqdmdiYomgS3JGNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFE3KM7:TT6=	NUTpepNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk2ODBpPkK2NVE6PTByPD;hQi=>
U2OS	M1fOcGZ2dmO2aX;uJIF{e2G7		MYmyJIhzew>?	MVLEbZNxdGGlZX3lcpQhd2ZiW{PIYYN6[2yxcHHtbY5mKG[{b32ge4lt\CC2eYDlJHNudyCneIDy[ZN{\WRiaX6gWVJQWyClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaTC9JFAvODF4MjFOwG0v	NHfve\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+
NIH3T3	Mn3hSpVv[3Srb36gZZN{[Xl?		MkXBN\|AhcHK\|	NYnmfXVEUW6qaXLpeIlwdiCxZjDTcY8hemWlZYD0c5IhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV41wKGGpb37pd5QhW0GJLXnu[JVk\WRiR2LFJIFkfGm4YYTpc44h[W[2ZYKgN\|AhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEKzJO69VS5?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{NkiwO{c,OjR5Mk[4NFc9N2F-
medulloblastoma cell	NHWySodCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3ixS\|M3KGi{cx?=	M{HlbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgVJRkcCtxLTDhcoQheDV\|LT:tJI1wfXOnIH3l[JVtdG:kbHHzeI9u[SClZXzsd{Bi\nSncjCzOkBpenNiYomgRpJlfSCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6wN\|A1KM7:TT6=	NYjkSW4xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFgzPzhpPkK4Olg5Ojd6PD;hQi=>
Shh Light2	MVTGeY5kfGmxbjDhd5NigQ>?			NYPYSm85SW62YXfvcol{fCCjY4Tpeol1gSCjdDDzcY9wfGinbnXkJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJHNpcCCOaXfoeFIh[2WubIOgZ48u\XiycnXzd4lv\yCJbHmt[IVx\W6mZX70JJJmeG:{dHXyJIdmdmViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCKaDDzbYdv[WyrbnegZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjB\|MzFOwG0v	M2W1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEmxOFU6Lz5{NES5NVQ2QTxxYU6=
Light2	MnywSpVv[3Srb36gZZN{[Xl?			M{foVWlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTHnnbJQzKGOnbHzzJIlvKFOqaDDjc45lcXSrb37l[EBu\WSrdX2gZpkhT2yrLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODN7IN88UU4>	Mlu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
Shh Light2	M3PYPGZ2dmO2aX;uJIF{e2G7			MojsTY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHscIlv\yCyYYToe4F6KGmwIH3veZNmKFOqaDDMbYdpfDJiY3XscJMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEO5NkDPxE1w	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd\|NkC2N{c,Ojd5M{[wOlM9N2F-
ASZ001	NWC1XYF7TnWwY4Tpc44h[XO\|YYm=		MkWxOFghcHK\|	M4WzdGlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIFHTXlAxOSClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC5yNDFOwG0v	Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
NIH/3T3	NWfTcppJTnWwY4Tpc44h[XO\|YYm=		MXO0PEBpenN?	MlGxRY51[WexbnnzeEBi[3Srdnn0fUBifCCVbX:gdoVk\XC2b4KgbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCqYYLic5JqdmdiR2LFMWx2[yCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFODRz3pcoR2[2WmIFjoJJNq\26jbHnu[{Bx[XSqd3H5JJBz\WmwY4XiZZRm\CC5aYToJINmdGy\|IH\vcIxwf2WmIHL5JHNCTyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wOFYh\|ryPLh?=	MmPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUeyO\|UoRjJ7OEW3Nlc2RC:jPh?=
Light2	NUHkNYp3TnWwY4Tpc44h[XO\|YYm=		MoHQN\|AhcHK\|	M4rlSmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTHnnbJQzKGOnbHzzJIlvKFOqaDDjc45lcXSrb37l[EBu\WSrdX2gZYZ1\XJiM{CgbJJ{KGK7IFfsbU1T\W6rbHzhJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEWg{txONg>?	NVfDVlFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVkzPTdpPkOwNFk6OjV5PD;hQi=>
C3H10T1/2	M3n4[GZ2dmO2aX;uJIF{e2G7		NGe0bmQ3KGSjeYO=	MYnJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6NW2nZHnheIVlKGSrZn\ldoVvfGmjdHnvckBw\iCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iU1HHMYlv\HWlZXSgRWxRKGGldHn2bZR6KGGodHXyJFYh\GG7czDifUBkcGWvaXz1cYlv\XOlZX7j[U1j[XOnZDDhd5NigSxiSVO1NEA:KDBwMEWg{txONg>?	MkPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOUmyOVcoRjNyMEm5NlU4RC:jPh?=
DaOY	M{[ycGZ2dmO2aX;uJIF{e2G7		M{\O[FQ5KGi{cx?=	NUXrbpNoUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hcHWvYX6gSIFQYSClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC5yOE[g{txONg>?	Mn;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
C3H10T1/2	M33v[mZ2dmO2aX;uJIF{e2G7		NV\VZ4poOSCqch?=	NFXmN3dKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIFOzTFExXDFxMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4heHW{bX;ydIhidWmwZT3pcoR2[2WmIHnuZ5Jm[XOnIHnuJIFtc2GuaX7lJJBpd3OyaHH0ZZNmKGyndnXsJJV{cW6pIFPEVE1{fGG{IHHzJJN2[nO2cnH0[UBxemW2cnXheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IID1do1wenCqYX3pcoUh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOUBl[XluIFnDOVAhRSByLkG0JO69VS5?	NI\3eog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm0O\|k{QSd-Mki5OFc6Ozl:L3G+
M210B4	MXfGeY5kfGmxbjDhd5NigQ>?		M1;FSlI1KGi{cx?=	M2XrbWlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF2yNVBDPCClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCSdHPoJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC5zNDFOwG0v	NUXYfFl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
M210B4	MVXGeY5kfGmxbjDhd5NigQ>?		NVq5c4ZIOjRiaILz	MXLJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCPMkGwRlQh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhT2yrMTDtVm5CKGW6cILld5Nqd25iYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{whUUN3MDC9JFAvOiEQvF2u	M2r4bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|E3Lz5{NEmwNFcyPjxxYU6=
Shh Light2	NGDCVmVHfW6ldHnvckBie3OjeR?=		MnvtNUBpeg>?	MmrWTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViU3joJGxq\2i2MjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4heHW{bX;ydIhidWmwZT3pcoR2[2WmIFfsbUBu\WSrYYTl[EB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgdJJmfHKnYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCydYLtc5JxcGGvaX7lJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IES4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjl6IN88UU4>	Mo[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NEe5N\|koRjJ6OUS3PVM6RC:jPh?=
NIH/3T3	M4nLV2Z2dmO2aX;uJIF{e2G7			MX\Jcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgbIFz[m:{aX7nJHNudyCGNEe3TEBufXSjboSgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFfsbUBuWk6DIHX4dJJme3Orb36gZpkhWlRvUFPSJI1mfGixZDygTWM2OCB;IEGuNVk3KM7:TT6=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW5NUc,Ojd6MUC1PVE9N2F-
S12	MmLNSpVv[3Srb36gZZN{[Xl?		M2Tl[FQ5KGi{cx?=	MUnJcohq[mm2aX;uJI9nKGi3bXHuJHNJUCCyYYToe4F6KGmwIH3veZNmKFNzMjDj[YxteyCjc4Pld5Nm\CCjczDHUGkudWWmaXH0[YQhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIFnfGW{IES4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZkhcW5icILld4Vv[2Vib3[gNE42KG2pL33MJIh2dWGwIHHsdIhiNTFvYXPp[EBodHmlb4Dyc5RmcW5uIFnDOVAhRSBzLke1JO69VS5?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR\|OEWyO{c,OjF2M{i1Nlc9N2F-
Calu6	NIrXW2JHfW6ldHnvckBie3OjeR?=		NIntU3I1KGi{cx?=	NGDZOZJRdGG\|bXGgZ49v[2WwdILheIlwdiCrbjDoeY1idiCFYXz1OkBk\WyuczD4[Y5w\3KjZoTl[EBqdiCwdXTlJI1wfXOnIHH0JFc2KG2pL3vnMEBxdyCkaXSgcYVie3W{ZXSgZYZ1\XJiNDDodpMheG:\|dDDmbYZ1cCCmb4PlMEBEeCB;IEKzJO69VS5?	M{XLOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2Nlk3Lz5zOUexOlI6PjxxYU6=
Calu-6	MVLGeY5kfGmxbjDhd5NigQ>?			M2jXS3Bt[XOvYTDjc45k\W62cnH0bY9vKGmwIFPhcJUuPiClZXzsd{B5\W6xZ4Lh[pRm\CCwdXTlJI1wfXOnIGDLM3BFKG2xZHXsJIF1KDd3IH3nM4toNCCybzDibYQh\m:{IEWg[IF6eyCvZXHzeZJm\CB2IHjyd{Bxd3O2IHzhd5Qh\G:\|ZTDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcEwhS3BiPTCyN{DPxE1w	MlLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{W3OFEoRjJyOEe1O\|QyRC:jPh?=
T47D	NH;RWlhEgXSxdH;4bYNqfHliYYPzZZk>		M33heVczKGi{cx?=	Mn7NR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOFEvOzRizszNMi=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
LS180	NUTmUlkxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3[zWlczKGi{cx?=	MlfKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOU{G4NEBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUuSiCjc4PhfUwhUUN3MDC9JFQ2KM7:TT6=	NXS4[VZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVkzPTdpPkOwNFk6OjV5PD;hQi=>
LS174T	NXfSdpMySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVe3NkBpenN?	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyVMUe0WEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES1MlgyKM7:TT6=	NUTvNXBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NlA2PTRpPkK2PFIxPTV2PD;hQi=>
BxPC3	NEXoTo9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHjqSlQ4OiCqcoO=	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEK6UFOzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEeuPVUh\|ryPLh?=	NHfMRo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkiyNFU2PCd-Mk[4NlA2PTR:L3G+
medulloblastoma cell	MVXBcpRqfHWvb4KgZZN{[Xl?			MVPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCvZXT1cIxw[myjc4TvcYEh[2WubIOgfIVvd2e{YX\0[YQhcW5iUITjbEAsNy1ibX;1d4Uh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6geJVud3Jidn;seY1mKGG2IEGyMlUhdWdxa3esJJBwKGKrZD6=	M1fRU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2Nlk3Lz5zOUexOlI6PjxxYU6=
S12	MkTlSpVv[3Srb36gZZN{[Xl?		NWXCTpZyPDhiaILz	M2T3fGlvcGmkaYTpc44hd2ZiaIXtZY4hW0iKIIDheIh4[XliaX6gcY92e2ViU{GyJINmdGy\|IHHzd4V{e2WmIHHzJGdNUS2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSCrbjDwdoV{\W6lZTDv[kAyKG2pL33MJIh2dWGwIHHsdIhiNTFvYXPp[EBodHmlb4Dyc5RmcW5w	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR\|OEWyO{c,OjF2M{i1Nlc9N2F-
Shh Light2	NYXNbHlrTnWwY4Tpc44h[XO\|YYm=	NGi5dJQxNjFidV2=	NXj0[IJ6OzZiaILz	M4LaRWlvcGmkaYTpc44hd2ZiU33vMY1m\GmjdHXkJGhpKHOrZ37hcIxqdmdicHH0bJdigSCrbjDtc5V{\SCVaHigUIlocHR{IHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKEeuaUGtcXJPSSCneIDy[ZN{cW:wIHH0JFAvOSC3TTDt[YF{fXKnZDDh[pRmeiB\|NjDodpMh[nliUmStdXBEWiCjbnHsfZNqey5?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd\|NkC2N{c,Ojd5M{[wOlM9N2F-
SW1353	M2[xWWFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NWX1e3V6OTBidV2=	NIX1TWI1QCCqcoO=	Ml;lRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{GzOVMh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[XRiMUCgeW0h[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfU4>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
DaOY	M4TIdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NES4TWgyOCC3TR?=	NEX1S\|Q1QCCqcoO=	NXHIR5doSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEZW9[KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGG2IEGwJJVOKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkv	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
A549	NHLRNJNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MnXQNVAhfU1?	NXnBbGpzPDhiaILz	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZZQhOTBidV2gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeT6=	Ml;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUG0OVkoRjJ2NEmxOFU6RC:jPh?=
HCT116	NV72dHdbSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	MnrqNVAhfU1?	NYXrT5ZJPDhiaILz	NETySVFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEB2VSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6Ng>?	NH\nUlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5NVQ2QSd-MkS0PVE1PTl:L3G+
NIH/3T3	NH;NRW9HfW6ldHnvckBie3OjeR?=	MVixNEB2VQ>?		NGnQdlNKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve44hemWpdXzheIlwdiCxZjDtVHREUDFibWLORUBmgHC{ZYPzbY9vKGG2IEGwJJVONg>?	MoTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUG0OVkoRjJ2NEmxOFU6RC:jPh?=
MSC	NIXoW4FHfW6ldHnvckBie3OjeR?=	M33hblIxKHSxIEiwJJVO		MWrJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCPU1OgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94diC{ZXf1cIF1cW:wIH;mJIFtc2GuaX7lJJBpd3OyaHH0ZZNmKGG2IEKwJJRwKDhyIIXNMi=>	NWftVmVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVE1PTlpPkK0OFkyPDV7PD;hQi=>
SK-N-MC	MYTxTHRUKGG\|c3H5			M3u1XZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzzMi=>	MnrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	M1fBSpFJXFNiYYPzZZk>			MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzzMi=>	NV\qTZB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NIH3T3-Luc	Ml;tSpVv[3Srb36gZZN{[Xl?	MUSxJJVO	MXG0PEBpenN?	NEj5epFKdmirYnn0bY9vKG:oIIPtc{1u\WSrYYTl[EBp\WSpZXjv[{B{cWewYXzpcocheGG2aIfhfUBqdiCvb4Xz[UBPUUh\|VEOtUJVkKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaTDtVm5CKGW6cILld5Nqd25iYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhemWjbD30bY1mKFCFUjDhcoFtgXOrcz6=	M32ycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEm5OFg{Lz5{OUS5PVQ5OzxxYU6=
C3H10T1/2	MlXaSpVv[3Srb36gZZN{[Xl?		NV;NXXpsOjRiaILz	MVfJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6NW2nZHnheIVlKEeOSUGgcXJPSSCneIDy[ZN{cW:wIHnuJI1wfXOnIFOzTFExXDFxMjDj[YxteyCjZoTldkAzPCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nzJIlvKHC{ZYPlcoNmKG:oIDixVkw{[VJuNGOsO4FTMS15YT3t[ZRpgWxvMT2oLHIqNTZvbXX0bJltcGWydHHuMVIugWxrb3P0ZYh6\HKxLUHIMYlv\GWwLUStfYwhOy2qeXTyc5h6[mWwen;heIUv	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd\|MEm4OEc,OjR5M{C5PFQ9N2F-
C3H10T1/2	NH3VemxHfW6ldHnvckBie3OjeR?=		M4HnW\|I1KGi{cx?=	NVG0d2JnUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeT3t[YRq[XSnZDDHUGkyKG2UTlGg[ZhxemW\|c3nvckBqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBXTDNw	NXfkPJUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3N\|A6QDRpPkK0O\|MxQTh2PD;hQi=>
NIH/3T3	Mne4SpVv[3Srb36gZZN{[Xl?	MX6xNFAhdk1?	M1PMbVM3KGi{cx?=	NXLhdlZyUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve45z\We3bHH0bY9vKG:oIGPobE1qdmS3Y3XkJGdtcTFibWLORUBmgHC{ZYPzbY9vKGyndnXsd{BifCBzMECgcm0h[W[2ZYKgN\|YhcHK\|IHL5JHJVNXGSQ2KgZY5idHm\|aYOu	NYf0N2MzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4O\|M{ODNpPkK4PFc{OzB\|PD;hQi=>
C3H10T1/2	M3zSbmZ2dmO2aX;uJIF{e2G7	MYexNFAhdk1?	M3S3e\|M3KGi{cx?=	NXTuOHNzUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gV4hpNWmwZIXj[YQhT2yrMTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KGG2IEGwNEBvVSCjZoTldkA{PiCqcoOgZpkhWlRvcWDDVkBidmGueYPpd{4>	NXnqWlA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4O\|M{ODNpPkK4PFc{OzB\|PD;hQi=>
NIH/3T3	Mlj2SpVv[3Srb36gZZN{[Xl?	MUOxNFAhdk1?	Mo\DN\|YhcHK\|	MlyxTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKFOqaD3pcoR2[2WmIID0Z4gyKG2UTlGg[ZhxemW\|c3nvckBt\X[nbIOgZZQhOTByIH7NJIFnfGW{IEO2JIhzeyCkeTDSWE1yWEOUIHHuZYx6e2m\|Lh?=	M2rJWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN\|A{Lz5{OEi3N\|MxOzxxYU6=
C3H10T1/2	MlTqSpVv[3Srb36gZZN{[Xl?	MnPRNVAxKG6P	MVezOkBpenN?	Mn;JTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCFM1ixNHQyNzJiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiU3joMYlv\HWlZXSgdJRkcDFibWLORUBmgHC{ZYPzbY9vKGyndnXsd{BifCBzMECgcm0h[W[2ZYKgN\|YhcHK\|IHL5JHJVNXGSQ2KgZY5idHm\|aYOu	Mn\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
medulloblastoma cell	MnfIRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	M1;CdZVxKHSxIEOwJJVO	NFrHRWY4OiCqcoO=	NHTuV4dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIGD0Z4gsNy1icEWzMU8uKG2nZIXscI9jdGG\|dH;tZUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBxem:uaX\ldoF1cW:wIIXwJJRwKDNyIIXNJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmu	MnSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
medulloblastoma cell	MWXBdI9xfG:\|aYOgZZN{[Xl?			NXHFZ\|B3UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBud3W\|ZTDQeINpMy9vIIC1N{0wNSCvZXT1cIxw[myjc4TvcYEh[2WubIOgbY1xdGGwdHXkJIlvKGG2aIntbYMhdnWmZTDtc5V{\SCjdDCxNk42KG2pL3vnMEBqeCCkaXSg[o9zKDF3IHPvcpNm[3W2aY\lJIRigXNiYomgWHVPTUxiYYPzZZkv	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh5M{OwN{c,Ojh6N{OzNFM9N2F-
NIH/3T3	MVnGeY5kfGmxbjDhd5NigQ>?			MW\Jcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGW6cILld5Nm\CCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gbIVl\2Wqb3etbY5lfWOnZDDHcIkuOiCjY3P1cZVt[XSrb36gZZQhfGmyIH;mJJBzcW2jcomgZ4ltcWFiYomgSGFRUSC\|dHHpcolv\yCkYYPl[EBkd26ob3PhcEBucWO{b4Pjc5Bq[yCjbnHsfZNqey5?	M3nnUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEGwOVkyLz5{N{ixNFU6OTxxYU6=
NIH/3T3	MULGeY5kfGmxbjDhd5NigQ>?			MlTrTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gbIVl\2Wqb3etbY5lfWOnZDDTcY8uTUeIUDDjbYxq[XK7IITyZY5{dG:lYYTpc44h[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDjc45nd2OjbDDtbYNzd3Olb4DpZ{BidmGueYPpd{4>	NYjtdlNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
medulloblastoma cell	MoDLRY51cS22dX3vdkBie3OjeR?=			M1PVVmFvfGlvdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDQeINpMy9vIIC1N{0wNSCvZXT1cIxw[myjc4TvcYEh[2WubIOgbY1xdGGwdHXkJIlvKGG2aIntbYMhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCyNEBu\y:tZzygdI8h[WSvaX7pd5RmemWmIIT3bYNmKGSjaXz5JJZq[SCpYY\h[4UhdWWjc4Xy[YQh\X[ncomgc5Rp\XJiZHH5JIR2emmwZzDjc41xd3WwZDDkc5Nqdmdw	Mn3lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5M{m3NVQoRjJ7N{O5O\|E1RC:jPh?=
C3H10T1/2	NVHGTmJTTnWwY4Tpc44h[XO\|YYm=	MVS0MlEhfG9iMUCwNEBvVQ>?		Mn6xRYxtd3O2ZYLpZ{BqdmirYnn0bY9vKG:oIGPtc{BqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDweZJud3KyaHHtbY5mNWmwZIXj[YQhT2yrMTD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYYSgOE4yKHSxIEGwNFAhdk1iYomgdXBEeiCjbnHsfZNqey5?	M1rUNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEe0OVQyLz5{M{C3OFU1OTxxYU6=
C3H10T1/2	MXvGeY5kfGmxbjDhd5NigQ>?	MXi0MlEhfG9iMUCwNEBvVQ>?		MljTR49ueGW2aYTpeoUhcW6qaXLpeIlwdiCxZjDTcY8hcW5ibX;1d4UhSzOKMUDUNU8zKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV2FINWmwZIXj[YQhT2yrMTD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYYSgOE4yKHSxIEGwNFAhdk1iYomgdXBEWiCjbnHsfZNqey5?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NEW0NUc,OjNyN{S1OFE9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID

Western blot	Bcl-2 / Bax ; p53 / Cyclin D1 / p21 ; Gli1 / SOX2 / OCT4 ; p-GSK3β / GSK3β / p-Akt / Akt / Gli1 ; Fas / DR4 / DR5 / Cleaved PARP / Bcl-2 / Cleaved caspase-3 / PDGFRα	28195165 26418365 27143997 22087285
Immunofluorescence	Gli1 / Gli2	22087285
Growth inhibition assay	Cell viability	29042665

体内試験

GDC-0449 has been used to treat medulloblastoma in animal models. ^[2] GDC-0449 prevents the growth of primary pancreatic xenografts without non-specifically inhibiting pancreatic cell proliferation. Oral dosing of GDC-0449 causes tumor regressions in the Ptch(+/-) allograft model of medulloblastoma at doses ≥25 mg/kg and tumor growth inhibition at doses up to 92 mg/kg dosed twice daily in two ligand-dependent colorectal cancer models, D5123, and 1040830. Analysis of Hh pathway activity and PK/PD modeling reveals that GDC-0449 inhibits Gli1 with a similar IC50 in both the medulloblastoma and D5123 models (0.165 μM and 0.267 μM, respectively). Pathway modulation is linked to efficacy using an integrated PK/PD model revealing a steep relationship where > 50% of the activity of GDC-0449 is associated with >80% repression of the Hh pathway. ^[4]

お薦めの試験操作（参考用のみ）

細胞試験：^[2]	細胞株：MDCKII cells 濃度： 20 μM 反応時間：2 hours 実験の流れ：MDCKII cells are seeded into 24-well plates at a density of 3 × 10⁵ cells per well and are allowed to attach. Medium is then changed to that containing different drugs (50 μM VP, 50 μM indomethacin, or 20 μM GDC-0449 in DMSO or DMSO alone as control, and nonfluorescent calcein-AM is added to a final concentration of 1.0 μM and incubated at 37 °C for 2 hours. Cells are then washed twice with Ca²⁺, Mg²⁺-containing Hank's balanced salt solution buffer and lysed by shaking in 0.01% Triton X-100 in PBS buffer for 1 hour at room temperature or overnight at 4 °C. The lysate is then transferred into 96-well plates, and the fluorescence signal caused by the cell-derived calcein is quantified spectrophotometrically with a SpectraMax M5 Multi-Detection Readerusing an excitation wavelength of 495 nm and an emission wavelength of 515 nm. All manipulations are performed in the dark. All readings are expressed as mean ?SEM normalized to the control.
動物試験：^[4]	動物モデル：Ptch(+/-) allograft model, D5123 and 1040830 投薬量：~ 100 mg/kg 投与方法：Orally

細胞試験：^[2]

細胞株：MDCKII cells
濃度： 20 μM
反応時間：2 hours
実験の流れ：MDCKII cells are seeded into 24-well plates at a density of 3 × 10⁵ cells per well and are allowed to attach. Medium is then changed to that containing different drugs (50 μM VP, 50 μM indomethacin, or 20 μM GDC-0449 in DMSO or DMSO alone as control, and nonfluorescent calcein-AM is added to a final concentration of 1.0 μM and incubated at 37 °C for 2 hours. Cells are then washed twice with Ca²⁺, Mg²⁺-containing Hank's balanced salt solution buffer and lysed by shaking in 0.01% Triton X-100 in PBS buffer for 1 hour at room temperature or overnight at 4 °C. The lysate is then transferred into 96-well plates, and the fluorescence signal caused by the cell-derived calcein is quantified spectrophotometrically with a SpectraMax M5 Multi-Detection Readerusing an excitation wavelength of 495 nm and an emission wavelength of 515 nm. All manipulations are performed in the dark. All readings are expressed as mean ?SEM normalized to the control.

動物試験：^[4]

動物モデル：Ptch(+/-) allograft model, D5123 and 1040830
投薬量：~ 100 mg/kg
投与方法：Orally

参考	[1] Scales SJ, et al. Trends Pharmacol Sci. 2009, 30(6), 303-312. [2] Zhang Y, et al. Neoplasia. 2009, 11(1), 96-101. [3] Tian F, et al. Anticancer Res. 2012, 32(1), 89-94. [4] Wong H, et al. Clin Cancer Res. 2011, 17(14), 4682-4692. + 展開

溶解度 (25°C)

体外


体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O 混合させたのち直ちに使用することを推奨します。注文はこちらから: PEG300 Tween 80	12.5mg/mL

化学情報

分子量	421.3
化学式	C₁₉H₁₄Cl₂N₂O₃S
CAS No.	879085-55-9
Storage	3年	-20°C	粉
Storage	2年	-80°C	in solvent
Smiles	CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl

Vismodegib (GDC-0449) SDFをダウンロードする

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

臨床試験

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03610022	Recruiting	Drug: Treatment with vismodegib	Metastatic Basal Cell Carcinoma\|Locally Advanced Basal Cell Carcinoma	University Hospital Bordeaux	September 3 2018	Phase 4
NCT03035188	Completed	Drug: Vismodegib	Basal Cell Carcinoma	SRH Wald-Klinikum Gera GmbH	January 2017	Phase 2
NCT02781389	Completed	--	Basal Cell Carcinoma	University Hospital Essen\|OnkoDataMed GmbH	April 29 2016	--
NCT02593760	Completed	Other: Placebo\|Drug: Ruxolitinib\|Drug: Vismodegib	Myelofibrosis	Hoffmann-La Roche	January 25 2016	Phase 1
NCT02648048	Completed	Drug: Pirfenidone\|Drug: Vismodegib	Idiopathic Pulmonary Fibrosis	Hoffmann-La Roche	January 15 2016	Phase 1
NCT02436408	Completed	Drug: Vismodegib	Carcinoma Basal Cell	University of Michigan Rogel Cancer Center	July 15 2015	Phase 4

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):